CD8

BACKGROUND

Programmed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell lung cancer (aNSCLC). Nevertheless, the impact of the balance between circulating CD8

METHODS

The CD8

RESULTS

In the discovery cohort (N=75), the PERLS cut-off was 1.91, and 11% of patients were PERLS+. PERLS + correlated significantly with median progression-free survival (PFS) of 9.63 months (95% CI 7.82 to not reached (NR)) versus 2.69 months (95% CI 1.81 to 5.52; p=0.03). In an independent validation cohort (N=36), median PFS was NR (95% CI 7.9 to NR) versus 2.00 months (95% CI 1.3 to 4.5; p=0.04) for PERLS + and PERLS-, respectively; overall survival (OS) followed a similar but non-significant trend. In the pooled cohort (N=111), PERLS + correlated significantly with PFS and OS. PERLS did not correlate with outcome in the polychemotherapy cohort. PERLS did not correlate with clinical characteristics but was significantly associated with baseline circulating naïve CD4

CONCLUSIONS

Elevated PERLS, determined from a blood sample before immunotherapy, was correlated with benefit from PD-(L)1 blockers in aNSCLC.

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: BD: speakers bureaus or educational events from Roche, Pfizer, AstraZeneca, Chiesi, Amgen, Lilly; support for attending meetings and/or travel from AZ, Pfizer, Oxyvie. MN: no competing interest to declare, EA: support for attending meetings and/or travel from: Mundipharma; lectures and educational activities: Sanofi Genzymes. RF: senior advisory board meetings for MSD. LC, J-MJ, LB, JG, AD, F-XD: no competing interest to declare. LM: sponsored research: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Stilla, Inivata. Consulting, advisory role: Roche Diagnostics, Takeda, Roche. Lectures and educational activities: Bristol Myers Squibb, Tecnofarma, Roche, Takeda. Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche. Mentorship program with key opinion leaders: funded by AstraZeneca. CC: no competing interest to declare. AM: senior advisory board meetings for MSD, BMS, AstraZeneca/Medimmune, Sanofi, Pfizer, Roche/Genentech, Merck Serono. Consulting services to Sanofi, Roche/Genentech. Speakers bureau of MSD, BMS, AstraZeneca/Medimmune, Sanofi, Roche/Genentech, Merck Serono. BB: sponsored research at Gustave Roussy Cancer Center 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals. NC: sponsored research at Gustave Roussy Cancer Center from AstraZeneca, GSK, Roche, Sanofi, Cytune Pharma, Gilead, Servier.